NOT KNOWN DETAILS ABOUT IVACAFTOR

;In vivo: MK-4827 is properly tolerated in vivo and demonstrates efficacy as just one agent inside of a xenograft model of BRCA-one deficient cancer [1]. Also, MK-4827 strongly improves the outcome of radiation on many different human tumor xenografts, each p53 wild form and p53 mutant. The improvement of radiation response is observed in clinicall